Malondialdehyde in benign prostate hypertrophy: a useful marker?
Benign prostate hypertrophy (BPH) is the most common benign tumor in men due to obstruction of the urethra and, finally, uremia. Malondialdehyde (MDA) is a product derived from peroxidation of polyunsaturated fatty acids and related esters. Evaluation of MDA in serum represents a non-invasive biomarker of oxidative stress. Prostate-specific antigen (PSA) is a sensitive marker for prostatic hypertrophy and cancer. We analyzed MDA serum levels to evaluate the oxidative stress in BPH. To this end, 22 BPH patients and 22 healthy donors were enrolled. Data show an increase of MDA level in BPH patients and a positive correlation between PSA and MDA levels. In conclusion, we describe a previously unknown relationship between PSA and MDA as an index of inflammation and oxidative stress in BPH.
Merendino
Rosaria Alba
RA
Department of Human Pathology, University of Messina Medical School, University Hospital G. Martino, Italy.
Salvo
Francesco
F
Saija
Antonella
A
Di Pasquale
Giuseppe
G
Tomaino
Antonio
A
Minciullo
Paola Lucia
PL
Fraccica
Giuseppe
G
Gangemi
Sebastiano
S
D000368:Aged; D015415:Biomarkers; D006801:Humans; D008297:Male; D008315:Malondialdehyde / Q000097:blood*; D008875:Middle Aged; D018384:Oxidative Stress; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood* / Q000175:diagnosis* / Q000276:immunology
D015415:Biomarkers; D008315:Malondialdehyde; D017430:Prostate-Specific Antigen